Sangart's Series G Adds $50M Now, $50M Later for MP4 Drugs
By Staff Reports
Wednesday, April 20, 2011
San Diego-based Sangart Inc. brought in more than $50 million in new equity funding to boost work on its MP4 pegylated hemoglobin platform in hemorrhage and sickle cell disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.